The drug development landscape for vitiligo is sparse despite its social impact on individuals irrespective of race, ethnicity, or gender. Sometimes dubbed a “cosmetic condition,” years of research suggest vitiligo is an autoimmune disorder that could be triggered by an event (e.g., sunburn, illness, stress) or linked to specific genes. Jaime Polychrones at Clarivate explores more about the lack of treatments that are approved by the US Food and Drug Administration (FDA) for repigmentation of vitiligo lesions.